EP300 Regulates the SLC16A1-AS1-AS1/TCF3 Axis to Promote Lung Cancer Malignancies Through the Wnt Signaling Pathway

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Mar 22

PMID 38515708

Authors

Yunhao Sun

Jian Sun

Kaijun Ying

Jinjin Chen

Tingting Chen

Leilei Tao

Weigang Bian

Limin Qiu

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the regulatory mechanism of EP300 in the interaction between SLC16A1-AS1 and TCF3 to activate the Wnt pathway, thereby promoting malignant progression in lung cancer.

Methods: In lung cancer cell lines, SLC16A1-AS1 was knocked down, and the impact of this knockdown on the malignant progression of lung cancer cells was assessed through clonogenic assays, Transwell assays, and apoptosis experiments. The regulatory relationship between EP300 and SLC16A1-AS1 was investigated through bioinformatic analysis and ChIP experiments. The expression of SLC16A1-AS1 and TCF3 in 56 paired lung cancer tissues was examined using RT-qPCR, and their correlation was analyzed. The interaction between TCF3 and SLC16A1-AS1 was explored through bioinformatic analysis and CoIP experiments. Activation of the Wnt/β-catenin pathway was assessed by detecting the accumulation of β-catenin in the nucleus through Western blotting. The role of EP300 in regulating the effect of SLC16A1-AS1/TCF3-mediated Wnt/β-catenin signaling on lung cancer malignant progression was validated through in vitro and in vivo experiments.

Results: SLC16A1-AS1 is highly expressed in lung cancer and regulates its malignant progression. EP300 mediates histone modifications on the SLC16A1-AS1 promoter, thus controlling its expression. SLC16A1-AS1 exhibits specific interactions with TCF3, and the SLC16A1-AS1/TCF3 complex activates the Wnt/β-catenin pathway. EP300 plays a critical role in regulating the impact of SLC16A1-AS1/TCF3-mediated Wnt/β-catenin signaling on lung cancer malignant progression.

Conclusion: EP300 regulates the SLC16A1-AS1/TCF3-mediated Wnt/β-catenin signaling pathway, influencing the malignant progression of lung cancer.

Citing Articles

Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.

Bi L, Wang X, Li J, Li W, Wang Z MedComm (2020). 2025; 6(3):e70080.

PMID: 39991629 PMC: 11843169. DOI: 10.1002/mco2.70080.

References

Liu H, Lu S, Guo Z, Zhang Z, Ye X, Du Q . lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer. J Investig Med. 2019; 68(1):52-59. PMC: 6996107. DOI: 10.1136/jim-2019-001080. View

Huang L, Li L, Cheng B, Xing T . SLC38A6, regulated by EP300-mediated modifications of H3K27ac, promotes cell proliferation, glutamine metabolism and mitochondrial respiration in hepatocellular carcinoma. Carcinogenesis. 2022; 43(9):885-894. DOI: 10.1093/carcin/bgac061. View

Thangudu S, Yu C, Lee C, Liao M, Su C . Magnetic, biocompatible FeCO nanoparticles for T2-weighted magnetic resonance imaging of in vivo lung tumors. J Nanobiotechnology. 2022; 20(1):157. PMC: 8952886. DOI: 10.1186/s12951-022-01355-3. View

de Almeida Nagata D, Chiang E, Jhunjhunwala S, Caplazi P, Arumugam V, Modrusan Z . Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. Cell Rep. 2019; 27(1):269-281.e4. DOI: 10.1016/j.celrep.2019.03.008. View

Feng H, Zhang X, Lai W, Wang J . Long non-coding RNA SLC16A1-AS1: its multiple tumorigenesis features and regulatory role in cell cycle in oral squamous cell carcinoma. Cell Cycle. 2020; 19(13):1641-1653. PMC: 7469610. DOI: 10.1080/15384101.2020.1762048. View

Broderick S . Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer. Thorac Surg Clin. 2020; 30(2):215-220. DOI: 10.1016/j.thorsurg.2020.01.001. View

Tian J, Hu D . LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival. Clin Res Hepatol Gastroenterol. 2021; 45(2):101490. DOI: 10.1016/j.clinre.2020.07.001. View

Mao Y, Yang D, He J, Krasna M . Epidemiology of Lung Cancer. Surg Oncol Clin N Am. 2016; 25(3):439-45. DOI: 10.1016/j.soc.2016.02.001. View

Raisner R, Bainer R, Haverty P, Benedetti K, Gascoigne K . Super-enhancer acquisition drives oncogene expression in triple negative breast cancer. PLoS One. 2020; 15(6):e0235343. PMC: 7316302. DOI: 10.1371/journal.pone.0235343. View

10.

Krug B, De Jay N, Harutyunyan A, Deshmukh S, Marchione D, Guilhamon P . Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. Cancer Cell. 2019; 35(5):782-797.e8. PMC: 6521975. DOI: 10.1016/j.ccell.2019.04.004. View

11.

Wang N, Yu C, Xu T, Yao D, Zhu L, Shen Z . Self-assembly of DNA nanostructure containing cell-specific aptamer as a precise drug delivery system for cancer therapy in non-small cell lung cancer. J Nanobiotechnology. 2022; 20(1):486. PMC: 9675138. DOI: 10.1186/s12951-022-01701-5. View

12.

Li Y, Zhu H, Du Y, Zhao H, Wang L . Silencing lncRNA SLC16A1-AS1 Induced Ferroptosis in Renal Cell Carcinoma Through miR-143-3p/SLC7A11 Signaling. Technol Cancer Res Treat. 2022; 21:15330338221077803. PMC: 8854231. DOI: 10.1177/15330338221077803. View

13.

Durbin A, Wang T, Wimalasena V, Zimmerman M, Li D, Dharia N . EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma. Cancer Discov. 2021; 12(3):730-751. PMC: 8904277. DOI: 10.1158/2159-8290.CD-21-0385. View

14.

Yu Z, Tang H, Chen S, Xie Y, Shi L, Xia S . Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy. Drug Resist Updat. 2023; 67:100915. DOI: 10.1016/j.drup.2022.100915. View

15.

Jonna S, Subramaniam D . Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discov Med. 2019; 27(148):167-170. View

16.

Jin Z, Li H, Long Y, Liu R, Ni X . MicroRNA-1269 is downregulated in glioblastoma and its maturation is regulated by long non-coding RNA SLC16A1 Antisense RNA 1. Bioengineered. 2022; 13(5):12749-12759. PMC: 9275873. DOI: 10.1080/21655979.2022.2070581. View

17.

Chen C, Chen Q, Wu J, Zou H . H3K27ac-induced FOXC2-AS1 accelerates tongue squamous cell carcinoma by upregulating E2F3. J Oral Pathol Med. 2021; 50(10):1018-1030. DOI: 10.1111/jop.13232. View

18.

Wang X, Sun M, Gao Z, Yin L, Pu Y, Zhu Y . N-nitrosamines-mediated downregulation of LncRNA-UCA1 induces carcinogenesis of esophageal squamous by regulating the alternative splicing of FGFR2. Sci Total Environ. 2022; 855:158918. DOI: 10.1016/j.scitotenv.2022.158918. View

19.

Jiang B, Liu Q, Gai J, Guan J, Li Q . LncRNA SLC16A1-AS1 regulates the miR-182/PDCD4 axis and inhibits the triple-negative breast cancer cell cycle. Immunopharmacol Immunotoxicol. 2022; 44(4):534-540. DOI: 10.1080/08923973.2022.2056482. View

20.

Long Y, Li H, Jin Z, Zhang X . LncRNA SLC16A1-AS1 is Upregulated in Glioblastoma and Promotes Cancer Cell Proliferation by Regulating miR-149 Methylation. Cancer Manag Res. 2021; 13:1215-1223. PMC: 7882451. DOI: 10.2147/CMAR.S264613. View